KORU Medical Posts 20% Revenue Growth, Expands Beyond Ig Therapy
Event summary
- KORU Medical reported 20% revenue growth in Q4 and full-year 2025, with net revenues reaching $41.1 million.
- Adjusted EBITDA turned positive at $0.6 million, a 124% improvement from the prior year.
- Received 510(k) clearance for UCB RYSTIGGO®, expanding its platform beyond immunoglobulin therapy.
- Initiated 2026 guidance projecting 15–22% revenue growth to $47.5–$50.0 million.
- Ending cash balance of $8.9 million, reflecting a 63% improvement in annual cash usage.
The big picture
KORU Medical's strong financial performance reflects the growing demand for subcutaneous immunoglobulin therapy and its successful expansion into broader therapeutic areas. The company's ability to achieve positive adjusted EBITDA and initiate optimistic 2026 guidance underscores its strategic shift towards a more scalable business model. The medical technology sector continues to favor companies that can balance innovation with operational efficiency, and KORU Medical's recent milestones position it favorably within this competitive landscape.
What we're watching
- Market Expansion
- Whether KORU Medical can sustain its 80% international core growth and penetrate new geographic markets.
- Regulatory Success
- The pace at which KORU Medical secures additional clearances for new therapeutic indications.
- Operational Efficiency
- How the company manages material costs and tariffs to maintain gross margins amid higher expenses.
Related topics